Novo Nordisk inks outcomes-based contract with pharmacy benefit manager for Victoza

Novo Nordisk (NYSE:NVO) said today that it inked a value-based contract for its Type II diabetes drug, Victoza, with pharmacy benefit manager Prime Therapeutics.

The agreement is part of Prime’s CareCentered Contract program. Under the terms of the deal, Prime will evaluate Victoza’s efficacy and will reimburse commercial clients if certain measures aren’t met, according to the company.

Get the full story at our sister site, Drug Delivery Business News.

The post Novo Nordisk inks outcomes-based contract with pharmacy benefit manager for Victoza appeared first on MassDevice.

from MassDevice http://ift.tt/2BiUEea